MedWatch

Solomon: Transforming moment for the company

CEO calls the recommendation of the Zealand Pharma-developed diabetes drug Lyxumia a transforming moment. He also says that the Danish company has a “good” royalty-deal in place with its partner Sanofi and reveals the company’s next Lyxumia.

Foto: Niels Hougaard / Jyllands-Posten

David Solomon, CEO of Zealand Pharma, was a happy man, when Medwatch spoke to him moments after it was announced that the company’s diabetes drug Lyxumia had been recommended for approval by an EMA medical committee.

“It is a transforming moment for the company. It is an exciting moment for Denmark. Zealand will see a significant turnover from this, we have a deal in place with Sanofi guaranteeing us double-digit royalties, so it will have a positive effect on the Danish economy,” he says, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier